(via TheNewswire)
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
Chronic dosing over a 12-week treatment period
Will assess weight loss and blood glucose level control
Efficacy through possible brain absorption delivery enhancement to be assessed
The contract for the Study has been awarded to a third-party,
Detailed information of the 12 Study arms is as noted:
Group 1:DehydraTECH-CBD (composition “A”)
Group 2:DehydraTECH-CBD (composition “B”)
Group 3:DehydraTECH-CBD (composition “C”)
Group 4:DehydraTECH-CBD (composition “D”)
Group 5:DehydraTECH-GLP-1 (re-formulated Rybelsus“E”)
Group 6:DehydraTECH-GLP-1 (re-formulated Rybelsus“F”)
Group 7:DehydraTECH-GLP-1 (pure semaglutide “G”)
Group 8:DehydraTECHGLP-1 (pure liraglutide “H”)
Group 9: Combination of one of E, F, or G and one of A, B, C, or D (TBD)
Group 10: Combination of H and one of A, B, C, or D (TBD)
Group 11: Vehicle (placebo) arm
Group 12: Positive control arm
Each arm of the Study will be dosed for an 8-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as
Study arms 9 and 10 will have a later start-date due to some information outputs required from the other Study arms before they and study arms 11 and 12 can commence. The Company will provide an update when animal dosing has begun.
In previous animal research with two other molecules, including cannabidiol,
Recent researchhas indicated “that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R–expressing neurons in the arcuate nucleus to produce weight loss.”
About
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016,
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the
INVESTOR CONTACT:
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source